Bleomycin, etoposide, and cisplatin for three cycles compared with etoposide and cisplatin for four cycles in good-risk germ cell tumors: Is there a preferred regimen? [5]

Journal of Clinical Oncology

Volumn 24, Issue 16, 2006, Pages 2597-2598

  Einhorn, Lawrence H ^a   Foster, Richard S ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; PLATINUM; ANTINEOPLASTIC AGENT;

ANOREXIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DYSPNEA; GERM CELL TUMOR; HUMAN; INFERTILITY; KIDNEY FUNCTION; LETTER; LUNG FUNCTION TEST; LUNG TOXICITY; METASTASIS; NAUSEA; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; TERATOMA; TREATMENT RESPONSE; DRUG ADMINISTRATION; MALE; NEOPLASM; NOTE; RISK ASSESSMENT; RISK FACTOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK ASSESSMENT; RISK FACTORS;

EID: 33744973343     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.05.6184     Document Type: Letter

References (16)

1. Kondagunta GV, Bacik J, Bajorin DF, et al: Etoposide and cisplatin chemotherapy for metastatic good-risk germ cell tumors. J Clin Oncol 23:9290-9294, 2005
2. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
3. Xiao H, Mazumdar M, Bajorin DF, et al: Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. J Clin Oncol 15:2553-2558, 1997
4. Einhorn LH, Williams SD, Loehrer PJ, et al: Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: A Southeastern Cancer Study Group protocol. J Clin Oncol 7:387-391, 1989
5. Saxman SB, Finch D, Gonin R, et al: Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide and cisplatin in favorable prognosis germ cell tumors: The Indiana University experience. J Clin Oncol 16:702-706, 1998
6. deWit R, Roberts T, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3- or 5-day schedule in good prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary tract cancer co-operative group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001
7. Loehrer PJ, Johnson D, Elson P, et al: Importance of bleomycin in favorable prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 13:470-476, 1995
8. deWit R, Stoter G, Kaye SB, et al: Importance of bleomycin in combination chemotherapy for good prognostic testicular non-seminoma: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Co-operative Group. J Clin Oncol 15:1837-1843, 1997
9. Hinton S, Catalone PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
10. O'Sullivan JM, Huddart RA, Norman AR, et al: Predicting the risk of bleomycin lung toxicity in patients with germ cell tumors. Ann Oncol 14:91-96, 2003
11. Bajorin DF, Bosl GJ: Bleomycin in germ cell tumor therapy: Not all regimens are created equal. J Clin Oncol 15:1717-1719, 1997
12. Culine S, Kerbrat P, Bouzy J, et al: The optimal chemotherapy regimen for good-risk metasatic non-seminomatous germ cell tumors (MNSGCT) is 3 cycles of bleomycin, etoposide, and cisplatin: Mature results of a randomized trial. Proc Am Soc Clin Oncol 21:382, 2003 (abstr 1536)
13. Levi JA, Raghavan D, Harvey V, et al: The importance of bleomycin in combination chemotherapy for good prognosis germ cell carcinoma. J Clin Oncol 11:1300-1305, 1993
14. Baniel J, Foster RS, Gonin R, et al: Late relapse of testicular cancer. J Clin Oncol 13:1170-1176, 1995
15. George DW, Foster RS, Hromas RA, et al: Update on late relapse of germ cell tumor: A clinical and molecular analysis. J Clin Oncol 21:113-122, 2003
16. Schmoll HJ, Souchon R, Krege S, et al: European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 15:1377-1399, 2004